Form D · Biotechnology
OriGene Technologies, Inc.
Rockville, MD · CIK 0001557269
Offering snapshot reported Jun 9, 2015 · SEC filing
- Reported sold
- $17.1M Offering amount: $32.1M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 26, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2015 | Initial | $17,051,983 | No comparison | 5 | SEC filing |
| Mar 10, 2014 | Initial | $200,000 | No comparison | 5 | SEC filing |
| Mar 19, 2013 | Initial | $6,377,442 | No comparison | 5 | SEC filing |
| Sep 4, 2012 | Initial | $15,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-241371
Source: Form D, filed Jun 9, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tom Bluth | Director |
| Gene Dove | Executive |
| Lanchun Duan | Director |
| Anil Gupta | Director |
| Rich Hamer | Executive |
| Wei Wu He | Director, Executive |
| James Hu | Executive |
| Karl Kovacs | Executive |
| Beatrice Leung | Director |
| Ellen Shih | Director |
| Youmin Shu | Executive |
| Tony Su | Director |
| Amy Tang | Director |
| Quan Zhou | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9620 Medical Center Drive Suite 200
Rockville, MD, 20850
Rockville, MD, 20850